LCTX - Lineage Cell Therapeutics, Inc. News

Discover

LCTX

Lineage Cell Therapeutics, Inc.

1.11

30 x 1.10

28 x 1.11

bid

ask

0.03

2.63%

12:03 PM

timesize

Ytd	-33.53%
1y	16.84%

1.10

day range

1.14

0.93

52 week range

2.09

Open	1.12	Prev Close	1.14	Low	1.10	High	1.14	Mkt Cap	284.20M
Vol	242.10K	Avg Vol	1.51M	EPS	-0.17	P/E	-6.87	Forward P/E	-3.66
Beta	1.51	Short Ratio	35.21	Inst. Own	50.56%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	08-11	50-d Avg	1.26	200-d Avg	1.58	1yr Est	4.83

LCTX News

marketbeat.com

Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject' Cell Therapy Plan

Lineage Cell Therapeutics NYSEAMERICAN: LCTX used a conference call to outline its manufacturing str

seekingalpha.com

Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Stra

benzinga.com

Lineage Cell Therapeutics Updates COR1 Corneal Cell Transplant Program; Highlights Scalable Allogene

Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PTCOR1 Aims to Provide an "Off t

businesswire.com

Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc

businesswire.com

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Su

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc

benzinga.com

Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call

On Tuesday, Lineage Cell Therapeutics (AMEX:LCTX) discussed first-quarter financial results during i

marketbeat.com

Lineage Cell Therapeutics Q1 Earnings Call Highlights

Lineage Cell Therapeutics NYSEAMERICAN: LCTX reported first-quarter 2026 results and used its earnin

seekingalpha.com

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript

zacks.com

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Est

benzinga.com

Lineage Cell Therapeutics Q1 EPS $(0.03) Misses $(0.02) Estimate, Sales $1.725M Miss $3.602M Estimat

Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.03) per share which missed th

businesswire.com

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc

benzinga.com

Earnings Scheduled For May 12, 2026

businesswire.com

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc

businesswire.com

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innov

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc

businesswire.com

Lineage Announces Formation of Scientific Advisory Board

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc

prnewswire.com

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Pr

AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disea

benzinga.com

Service Properties Trust, ConocoPhillips And Other Big Stocks Moving Lower In Monday's Pre-Market Se

US stock futures up, Nasdaq 100 gains 100 pts. Service Properties Trust (SVC) drops 4% in pre-market

defenseworld.net

Defender Capital LLC. Buys Shares of 6,829,099 Lineage Cell Therapeutics, Inc. $LCTX

Defender Capital LLC. bought a new stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:

benzinga.com

HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX)

benzinga.com

Lineage Cell Therapeutics Expands Cell Transplant Pipeline With COR1

New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturi

businesswire.com

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc

benzinga.com

12 Health Care Stocks Moving In Wednesday's After-Market Session

benzinga.com

Lineage Cell Therapeutics Files Prospectus To Offer Up To $100M In Common Shares, Preferred Shares,

$100,000,000 Common SharesPreferred SharesDebt SecuritiesWarrants From time to time, we may offer up

benzinga.com

Lineage Cell Therapeutics Files $60M ATM Share Offering Prospectus Supplement

Other Events.On March 11, 2026, Lineage Cell Therapeutics, Inc. (the "Company") filed with t

defenseworld.net

Lineage Cell Therapeutics Q4 Earnings Call Highlights

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) used its quarterly conference call to highlight a long

benzinga.com

D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Raises Price Target to $3

D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy

seekingalpha.com

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript

zacks.com

Lineage Cell (LCTX) Reports Break-Even Earnings for Q4

Lineage Cell (LCTX) reported break-even quarterly earnings per share versus the Zacks Consensus Esti

benzinga.com

Lineage Cell Therapeutics Q4 Earnings Summary & Key Takeaways

benzinga.com

Lineage Cell Therapeutics Q4 EPS $0.00 Beats $(0.05) Estimate, Sales $6.600M Beat $2.577M Estimate

Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly earnings of $0.00 per share which beat the

businesswire.com

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides B

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc

benzinga.com

Earnings Scheduled For March 5, 2026

benzinga.com

A Look Ahead: Lineage Cell Therapeutics's Earnings Forecast

businesswire.com

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc

prnewswire.com

Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration

/PRNewswire/ -- USA News Group News Commentary - Global capital is officially rotating into "Longevi

benzinga.com

Snowflake, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

benzinga.com

D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target

D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy

benzinga.com

HC Wainwright & Co. Maintains Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

HC Wainwright & Co. analyst Joseph Pantginis maintains Lineage Cell Therapeutics (AMEX:LCTX)

benzinga.com

Lineage Cell Therapeutics Sold 12M Common Shares To Janus Henderson Investors At A Purchase Price Of

On November 12, 2025, Lineage Cell Therapeutics, Inc. (the "Company") sold 12,000,000 common

benzinga.com

Lineage Cell Therapeutics Q3 EPS $(0.13) Misses $(0.02) Estimate, Sales $3.681M Beat $2.300M Estimat

Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.13) per share which missed th

benzinga.com

Earnings Scheduled For November 6, 2025

benzinga.com

12 Health Care Stocks Moving In Monday's After-Market Session

benzinga.com

Lineage Cell Therapeutics Announces Launch Of A New Islet Cell Transplant Program Targeting Type 1 D

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology compa

benzinga.com

5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know

benzinga.com

D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target

D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy

benzinga.com

Lineage And William Demant Collaborate Through Investment To Develop ReSonance For Hearing Loss

Three-year term intended to advance preclinical development of ReSonanceUp to $12 million of develop

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com

D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target

D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy

benzinga.com

Update: Lineage Cell Therapeutics Q2 Adj. EPS $(0.07) Misses $(0.03) Estimate, Sales $2.765M Beat $1

Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.07) per share which missed th

benzinga.com

Lineage Cell Therapeutics Q2 EPS $(0.13) Misses $(0.03) Estimate, Sales $2.765M Beat $1.472M Estimat

Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.13) per share which missed th